![]() |
|
|
Vol. 290, Issue 2, 656-663, August 1999
Department of Pharmacology, Cornell University Weill Medical College, New York, New York
| |
Abstract |
|---|
|
|
|---|
We had shown that bradykinin (BK) generated by cardiac sympathetic nerve endings (i.e., synaptosomes) promotes exocytotic norepinephrine (NE) release in an autocrine mode. Because the synaptosomal preparation may include sensory C-fiber endings, which BK is known to stimulate, sensory nerves could contribute to the proadrenergic effects of BK in the heart. We report that BK is a potent releaser of NE from guinea pig heart synaptosomes (EC50 ~20 nM), an effect mediated by B2 receptors, and almost completely abolished by prior C-fiber destruction or blockade of calcitonin gene-related peptide and neurokinin-1 receptors. C-fiber destruction also greatly decreased BK-induced NE release from the intact heart, whereas tyramine-induced NE release was unaffected. Furthermore, C-fiber stimulation with capsaicin and activation of calcitonin gene-related peptide and neurokinin-1 receptors initiated NE release from cardiac synaptosomes, indicating that stimulation of sensory neurons in turn activates sympathetic nerve terminals. Thus, BK is likely to release NE in the heart in part by first liberating calcitonin gene-related peptide and Substance P from sensory nerve endings; these neuropeptides then stimulate specific receptors on sympathetic terminals. This action of BK is positively modulated by cyclooxygenase products, attenuated by activation of histamine H3 receptors, and potentiated at a lower pH. The NE-releasing action of BK is likely to be enhanced in myocardial ischemia, when protons accumulate, C fibers become activated, and the production of prostaglandins and BK increases. Because NE is a major arrhythmogenic agent, the activation of this interneuronal signaling system between sensory and adrenergic neurons may contribute to ischemic dysrhythmias and sudden cardiac death.
| |
Introduction |
|---|
|
|
|---|
We
had shown that bradykinin (BK) generated by cardiac sympathetic nerve
endings (i.e., synaptosomes) promotes exocytotic norepinephrine (NE)
release in an autocrine fashion (Seyedi et al., 1997
). Because the
synaptosomal fraction may also contain sensory C-fiber endings, which
BK is known to stimulate (Franco-Cereceda, 1988
; Geppetti, 1993
;
Imamura et al., 1996b
; Kopp et al., 1997
; Wood and Docherty, 1997
),
sensory nerves could play a role in the proadrenergic effects of BK in
the heart. A BK-initiated interaction between sensory and adrenergic
nerves would be important in myocardial ischemia. Indeed, myocardial
ischemia is known to be associated with an enhanced release of NE
(Schömig, 1990
; Imamura et al., 1994
, 1996a
), BK (Kimura et al.,
1973
; Matsuki et al., 1987
; Lamontagne et al., 1995
) and sensory
neurotransmitters, such as calcitonin gene-related peptide (CGRP) and
Substance P (Franco-Cereceda, 1988
, 1989; Milner et al., 1989
; Mair et
al., 1990
).
Accordingly, we investigated whether the presence of intact cardiac C fibers is a prerequisite for the BK-induced release of NE from sympathetic nerve endings and whether this action is affected by specific blockade of sensory transmitter receptors. Furthermore, we assessed possible modulatory mechanisms capable of up- or down-regulating BK-initiated NE release in the heart.
Our findings identify a novel BK-promoted cross-talk system between
adrenergic and sensory nerve endings in the heart, whereby BK produced
at adrenergic terminals (Seyedi et al., 1997
) initiates a paracrine
release of CGRP and Substance P from C fibers, and these neuropeptides
signal back to adrenergic nerve endings to promote NE release. This
action of BK is mediated by B2 receptors, involves a cyclooxygenase-mediated step, is negatively modulated by
histamine H3 receptors, and is greatly
potentiated at a lower pH.
| |
Materials and Methods |
|---|
|
|
|---|
NE Release from Cardiac Synaptosomes.
Male Hartley guinea
pigs (Harlan Bioproducts for Science, Inc., Indianapolis, IN)
weighing 250 to 300 g were sacrificed by cervical dislocation
under light anesthesia with CO2 vapor in accordance with institutional guidelines. The rib cage was dissected away, and the heart was rapidly excised, freed from fat and connective tissue, and transferred to a Langendorff apparatus (Park et al., 1992
). Spontaneously beating hearts were perfused through the aorta for
15 min at constant pressure (40 cm of H2O) with
Ringer's solution at 37°C saturated with 100%
O2 (pH 7.5; Park et al., 1992
). This procedure
ensured that no blood traces remained in the coronary circulation. When
indomethacin was used, hearts were perfused with indomethacin (10 µM)
for an additional 10 min. In either case, at the end of the perfusion,
hearts were minced in ice-cold 0.32 sucrose containing 1 mM EGTA, pH
7.4. Synaptosomes were isolated as previously described (Seyedi et al.,
1997
). Minced tissue was digested with 40 mg collagenase (type 2;
Worthington Biochem. Corp., Freehold, NJ) per 10 ml of HEPES-buffered
saline solution (HBS) per gram of wet heart weight for 1 h at
37°C. HBS contained 1 mM pargyline to prevent enzymatic destruction
of synaptosomal NE. After low-speed centrifugation (10 min at
120g at 4°C), the resulting pellet was suspended in 10 volumes of 0.32 M sucrose and homogenized with a Teflon/glass
homogenizer. The homogenate was spun at 650g for 10 min at
4°C and the pellet rehomogenized and respun. The pellet containing
cellular debris was discarded, and the supernatants from the last two
spins were combined and equally subdivided into 10 to 12 tubes. Each
tube was centrifuged for 20 min at 20,000g at 4°C. This
pellet, which contained cardiac synaptosomes, was resuspended in HBS to
a final volume of 500 µl in the presence or absence of
pharmacological agents for a total of 20 min in a water bath at 37°C.
Each suspension functioned as an independent sample and was used only
once. In every experiment, one sample was untreated (control, basal NE
release), and others were incubated with drugs for 20 min. When
antagonists were used, samples were incubated with the antagonist for
20 min before incubation with the agonist. Controls were incubated for
an equivalent length of time without drugs. At the end of the
incubation period, each sample was centrifuged for 20 min
(20,000g at 4°C). The supernatant was assayed for NE
content by HPLC with electrochemical detection (Seyedi et al., 1997
).
The pellet was assayed for protein content by a modified Lowry
procedure (Seyedi et al., 1997
).
Capsaicin Pretreatment In Vivo.
Guinea pigs were
anesthetized with pentobarbital sodium (25 mg/kg i.p.) and artificially
ventilated with a rodent respirator (Harvard Apparatus), according to
institutional guidelines. Theophylline (100 mg/kg i.p.) was given to
counteract respiratory impairment. Capsaicin (total dose, 50 mg/kg
s.c.) was administered 6 h before in vitro experimentation; this
has been shown to cause a total loss of CGRP-containing nerves within
the heart (Imamura et al., 1996b
). Control animals received the same
treatment except for capsaicin. Hearts from control and
capsaicin-treated animals were excised and perfused in the Langendorff
apparatus as described above. Most hearts were used for the preparation
of synaptosomes. Others were perfused with BK (1 µM) for 20 min to
determine whether C-fiber destruction affects the ability of BK to
elicit NE release from the intact heart. Destruction of C fibers in
capsaicin-pretreated hearts was ascertained by measuring NE overflow in
response to a 20-min capsaicin (1 µM) perfusion. NE availability in
capsaicin-pretreated hearts was assessed by measuring NE overflow in
response to a 20-min tyramine (1 µM) perfusion. NE overflow into the
coronary effluent was assayed by HPLC (as described above) before and
during perfusions with capsaicin, BK, and tyramine.
Statistics. Values are expressed as mean percent increases above basal NE release (synaptosomes) or basal NE overflow (isolated hearts) ± S.E. There were no statistically significant differences in basal NE release among the various experiments. Analysis by one-way ANOVA was used, followed by post hoc testing (Dunnett's test). In two instances (see Figs. 7 and 8), paired and unpaired Student's t tests were used, respectively. A value of p < .05 was considered statistically significant. The EC50 for BK-induced NE release was calculated by nonlinear regression curve fitting with the GraphPad Prism program (GraphPad Software, Inc., San Diego, CA).
Drugs and Chemicals. CGRP, CGRP8-37, and Substance P were purchased from Peninsula Labs., Inc. (Belmont, CA). Capsazepine, Hoe 140, imetit dihydrobromide, and thioperamide maleate were purchased from Research Biochemicals International (Natick, MA). Atropine sulfate, BK, [des-arg9leu8]BK, capsaicin, indomethacin, theophylline, and tyramine hydrochloride were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). CP 99,994 was a gift from Pfizer Central Research. Capsaicin was dissolved in 100% ethanol. Capsazepine and indomethacin were dissolved in dimethyl sulfoxide. Further dilutions were made with distilled water; at the concentration used, dimethyl sulfoxide and ethanol did not affect mediator release.
| |
Results |
|---|
|
|
|---|
Release of Synaptosomal NE by BK and Capsaicin.
Incubation of
the cardiac synaptosomal fraction with 1 to 100 nM BK caused a
concentration-dependent NE release that reached a maximum of ~32%
above basal level (EC50 ~20 nM; Fig.
1). The concentration-response curve was
not modified in the presence of atropine (1 µM; Fig. 1). The BK
B2-receptor antagonist HOE 140 (3 nM;
pA2) caused a marked downward shift in
the BK concentration-response curve. In contrast, the
B1-receptor antagonist
[des-arg9leu8]BK (1 µM;
2.5 × pA2) failed to shift the BK
concentration-response curve (Fig. 1).
|
|
|
Release of Synaptosomal NE by CGRP and Substance P.
Incubation
of the synaptosomal fraction with capsaicin or BK in the presence of
antagonists of the sensory neuropeptide transmitters CGRP and Substance
P greatly diminished the effects of capsaicin and BK. The CGRP-receptor
antagonist CGRP8-37 (1 µM;
pKi, 6.5-8.0; Bell and McDermott,
1996
) decreased the NE-releasing effects of capsaicin and BK by 50 to
60% (n = 6 + 6, p < .01). The
Substance P/tachykinin neurokinin-1
(NK1)-receptor antagonist CP 99,994 (100 nM;
pKi, 7.3-9.3; Regoli et al., 1994
)
decreased the NE-releasing effects of capsaicin and BK by ~60%
(n = 6 + 6, p < .01). As shown in Fig.
4, A and B, when these
neuropeptide-receptor antagonists were used in combination, at 5- and
10-fold greater concentrations (i.e., CGRP8-37 5 µM and CP 99,994 1 µM), the blockade of the NE-releasing effect of
capsaicin and BK remained at a 60 to 65% level.
|
Modulation of BK- and Capsaicin-Induced Release of NE from
Cardiac Synaptosomes.
Inhibition of cyclooxygenase with
indomethacin (10 µM) reduced the NE-releasing effect of capsaicin and
BK. As shown in Fig. 5, after
pretreatment with indomethacin, synaptosomes released ~70% less NE
than untreated controls in response to either capsaicin or BK.
|
|
|
BK-Enhanced NE Overflow from Isolated Guinea Pig Hearts:
Modification by Capsaicin Pretreatment.
We next determined whether
C-fiber destruction affects the ability of BK to elicit NE release from
the intact heart. As shown in Fig. 8A,
the overflow of NE from isolated guinea pig hearts increased by 48%
during a 20-min perfusion with BK (1 µM). In contrast, in hearts from
capsaicin-pretreated animals, NE overflow increased only by 17% in
response to BK (p < .001, by unpaired Student's
t test; Fig. 8A). Not shown in Fig. 8 is that NE overflow increased by 45.8 ± 12.2% in response to a 20-min perfusion with capsaicin (1 µM) but only by 10.5 ± 5.0% in
capsaicin-pretreated hearts (p < .05;
n = 4 + 4). In contrast, the increase in NE overflow elicited by a 20-min perfusion with tyramine (1 µM) was unaffected by
capsaicin pretreatment (Fig. 8B), indicating that the diminished BK
and/or capsaicin response in capsaicin-pretreated hearts was not caused
by a loss in NE availability.
|
| |
Discussion |
|---|
|
|
|---|
Our findings demonstrate that stimulation of cardiac sensory C fibers with BK elicits the release of NE from sympathetic nerve endings, an action attenuated by prior C-fiber destruction or by CGRP- and Substance P-receptor antagonists. This suggests that BK, at least in part, initiates the release of CGRP and Substance P from C fibers; these neuropeptides subsequently act on adrenergic nerve endings to promote NE release. This action of BK is mediated by B2 receptors; positively and negatively modulated by cyclooxygenase products and histamine H3 receptors, respectively; and greatly potentiated at a lower pH.
We had previously reported that BK promotes NE release from adrenergic
nerve endings in a preparation of cardiac synaptosomes (Seyedi et al.,
1997
). This synaptosomal fraction is likely to contain other types of
nerve endings, such as cholinergic terminals and unmyelinated sensory C
fibers. Inasmuch as atropine does not modify the NE-releasing effects
of BK (Seyedi et al., 1997
; see also Fig. 1), cholinergic nerves are
not likely to contribute to these effects. In contrast, sensory C
fibers are known to be highly sensitive to BK (Franco-Cereceda, 1988
;
Geppetti, 1993
; Wood and Docherty, 1997
). Thus, we questioned whether
the cardiac sympathomimetic effects of BK might be initiated in part by
an action on sensory nerves, subsequently relayed to adrenergic terminals.
First, we established that, in addition to its proexocytotic effects
(Kurz et al., 1997
; Seyedi et al., 1997
; Chulak et al., 1998
), BK
elicits the release of endogenous NE from cardiac adrenergic nerves
even in the absence of K+-induced depolarization.
We found this action to be as potent (EC50 ~20
nM) as the proexocytotic effect of BK (EC50 ~17
nM; Seyedi et al., 1997
) and mediated by B2
receptors. In fact, B2 receptors have been
consistently found to mediate the proadrenergic effects of BK (McDonald
et al., 1994
; Minshall et al., 1994
; Chulak et al., 1995
, 1998
; Poxton,
1995
; Dendorfer et al., 1996
; Boehm and Huck, 1997
; Rump et al., 1997
;
Seyedi et al., 1997
).
Next, we sought to demonstrate that chemical stimulation of cardiac
sensory C fibers results in NE release from adrenergic terminals. For
this we used capsaicin, a highly specific sensory neuron excitotoxin
and vanilloid-receptor agonist (Caterina et al., 1997
; Wood and
Docherty, 1997
). We found that incubation of the cardiac synaptosomal
fraction with capsaicin caused the release of endogenous NE, and this
effect was inhibited by the vanilloid-receptor blocker capsazepine
(Bevan et al., 1992
; Caterina et al., 1997
; Wood and Docherty, 1997
).
Moreover, prior destruction of sensory C fibers by pretreatment with
capsaicin in vivo (Imamura et al., 1996b
), greatly reduced NE release
in response to a subsequent capsaicin administration to the intact
heart and cardiac synaptosomes. This is the first demonstration that
stimulation of cardiac sensory neurons in turn activates sympathetic
nerve terminals.
Most important, we found that, analogous to capsaicin, nearly complete destruction of sensory C fibers markedly decreased the NE-releasing activity of BK, both in the intact heart and in the synaptosomal fraction. This decreased BK response was not caused by NE depletion. Indeed, we found that tyramine released the same amount of NE from control and capsaicin-pretreated hearts. These findings clearly indicate that sensory nerve terminals play an important role in the sympathomimetic effects of BK in the heart.
To identify the chemical signals by which sensory terminals may
communicate with adrenergic fibers, we used two neuropeptide-receptor antagonists, CGRP8-37 and compound CP 99,994, that specifically block the effects of CGRP and Substance P with
Kis in the high and low nanomolar
range, respectively (Regoli et al., 1994
; Bell and McDermott, 1996
). We
found that the administration of exogenous CGRP and Substance P
elicited the release of synaptosomal NE and that these effects were
inhibited by CGRP8-37 and CP 99,994, respectively. Furthermore, we found that the NE-releasing effects of
capsaicin and BK were markedly reduced by blockade of CGRP and
Substance P receptors. This suggests that BK ultimately releases NE in
the heart by first liberating CGRP and Substance P from sensory nerve
endings; these neuropeptides then stimulate specific receptors on
sympathetic nerve endings. Indeed, BK is known to release CGRP from
capsaicin-sensitive nerves in guinea pig atria (Geppetti et al., 1990
).
We found that the NE-releasing effect of BK was not further reduced
when CGRP8-37 and CP 99,994 were used in
combination at 5- and 10-fold greater concentrations. Similarly, a
small portion of the NE-releasing effect of BK persisted even after
destruction of C fibers. Thus, BK appears to act for the most part on
sensory C fibers and to a lesser extent directly on sympathetic nerve endings.
Prostaglandins are known to enhance the actions of BK on sensory
nerves. Indeed, sensory neurons are endowed with cyclooxygenase activity, and indomethacin attenuates the BK-stimulated release of CGRP
and Substance P from sensory neurons in culture (Vasko et al., 1994
)
and of CGRP from guinea pig atria (Geppetti et al., 1990
). Furthermore,
the BK-induced release of Substance P in the kidney is a
prostaglandin-dependent phenomenon (Kopp et al., 1997
), and the
cyclooxygenase system contributes to enhanced BK responsiveness of
chemosensitive nerve endings in heart failure (Schultz et al., 1997
).
Accordingly, we assessed whether endogenous prostaglandins play a role
in the C-fiber-dependent sympathomimetic effects of BK in the heart. We
found that pretreatment of isolated guinea pig hearts with indomethacin
markedly reduced the ability of BK to release NE from the synaptosomal
fraction. Analogous to BK, the NE-releasing effect of capsaicin was
also significantly decreased. Thus, the C-fiber-initiated release of NE
from cardiac sympathetic nerve terminals comprises a
cyclooxygenase-dependent step. Conceivably, cyclooxygenase products
could augment the release of neuropeptide transmitters from activated
sensory fibers (Vasko et al., 1994
). Also, prostaglandin-induced
posttranslational modifications could increase the sensitivity of the
vanilloid and B2 receptors and associated
channels (Wood and Docherty, 1997
).
We had previously characterized the function of inhibitory histamine
H3 receptors on cardiac sensory C fibers (Imamura
et al., 1996b
). These receptors, activated by histamine released by
CGRP from adjacent cardiac mast cells, play a major role in a
regulatory negative-feedback loop that modulates neurotransmitter release from sensory nerve endings. Thus, we questioned whether this
regulatory system may also modulate the sympathomimetic effect of BK in
the heart. Our findings suggest that this may be the case. Indeed, the
selective histamine H3-receptor agonist imetit attenuated the release of synaptosomal NE elicited by C-fiber stimulation with BK or capsaicin, and this effect was prevented by
blockade of histamine H3 receptors with
thioperamide. Although this demonstrates the presence of inhibitory
histamine H3 receptors, it does not distinguish
between receptors located on sensory (Imamura et al., 1996b
) and
adrenergic (Imamura et al., 1995
) nerve endings in the heart, because
histamine H3-receptor stimulation at either or
both locations would ultimately result in a decreased NE release. Inasmuch as CGRP released from sensory endings in the heart elicits the
release of histamine from local mast cells (Imamura et al., 1996b
), it
is likely that histamine H3 receptors become
activated when C fibers are stimulated by BK, so that the release of
CGRP and thus NE would be curtailed. Nevertheless, we could not
directly test this hypothesis because histamine
H3 receptors in the synaptosomal preparation
would not be expected to be endogenously activated, given the absence
of intact mast cells.
Myocardial ischemia is associated with activation of C fibers and CGRP
release, probably via an increase in cation conductance (Franco-Cereceda, 1988
; Franco-Cereceda and Lundberg, 1992
; Wood and
Docherty, 1997
). This most likely occurs because tissue pH decreases in
myocardial ischemia as CO2 and protons accumulate (Ichihara et al., 1991
; Opie, 1991
), and protons are known to activate
vanilloid-gated ion channels (Wood and Docherty, 1997
). Because both BK
production (Kimura et al., 1973
; Matsuki et al., 1987
; Lamontagne et
al., 1995
) and NE release (Schömig, 1990
; Imamura et al., 1994
,
1996a
) are enhanced in myocardial ischemia, a lower tissue pH could
potentiate the BK-initiated, C-fiber-mediated NE release. Our findings
favor this hypothesis. In fact, at pH 5.5 and 6.5 (comparable to tissue
pH values found in myocardial ischemia; Hirche et al., 1980
; Ichihara
et al., 1991
; Opie, 1991
), much less BK was needed to produce an
increase in NE release equal to that observed at pH 7.4. Accordingly, a
lower tissue pH could be mechanistically important in the BK-induced
promotion of NE release in ischemia-reperfusion models (Hatta et al.,
1999
). Because protons increase the release of neuropeptides and
prostaglandins (Franco-Cereceda and Lundberg, 1992
; Wood and Docherty,
1997
) and prostaglandins in turn augment peptide release
(Franco-Cereceda et al., 1994
), both of these factors could be involved
in the pH-mediated potentiation of BK-initiated NE release. In addition to the effect of lower pH on C fibers, our data would also be consistent with a direct effect of lower pH on sympathetic nerve terminals. However, the fact that acidosis does not influence the
nicotine-induced and electrically stimulated release of NE from
isolated hearts (Dart and Riemersma, 1989
; Kruger et al., 1995
) would
seem to exclude this possibility.
In conclusion (see Fig. 9), our data
suggest that BK initiates the antidromic release of CGRP and Substance
P by activating B2 receptors on afferent sensory
C fibers (Maggi, 1995
); these neuropeptides subsequently act on CGRP
and NK1 receptors at adrenergic endings and
promote NE release. In addition, but probably to a smaller extent, BK
releases NE by directly stimulating B2 receptors at adrenergic terminals (Seyedi et al., 1997
). Because BK can be
generated by cardiac sympathetic nerve endings (Seyedi et al., 1997
),
our findings identify a novel paracrine cross talk between adrenergic
and sensory nerve endings in the heart, whereby BK formed at
sympathetic endings activates sensory fibers that in turn stimulate
sympathetic endings via neuropeptide release. Histamine released from
local mast cells by CGRP (Imamura et al., 1996b
) acts at inhibitory
histamine H3 receptors located at both adrenergic (Imamura et al., 1995
) and sensory (Imamura et al., 1996b
) nerve endings as part of a BK-initiated negative-feedback loop that ultimately limits NE release. In contrast, cyclooxygenase products appear to augment the sympathomimetic action of BK in the heart. Because the effect of BK is potentiated at a lowered pH, the
NE-releasing action of BK is likely to be greatly enhanced in the
setting of myocardial ischemia, where protons accumulate (Hirche et
al., 1980
; Ichihara et al., 1991
; Opie, 1991
), C fibers become
activated (Franco-Cereceda, 1988
; Milner et al., 1989
; Franco-Cereceda
and Lundberg, 1992
; Wood and Docherty, 1997
), and the production of prostaglandins (Berger et al., 1976
, 1977
; Kraemer et al., 1976
) and BK
(Kimura et al., 1973
; Matsuki et al., 1987
; Lamontagne et al., 1995
)
increases. Because NE is a major arrhythmogenic agent (Schömig,
1990
; Schömig et al., 1991
; Imamura et al., 1996a
), the
activation of this sensory/adrenergic interneuronal cross-talk system
may contribute to ischemic dysrhythmias and sudden cardiac death.
|
| |
Acknowledgments |
|---|
We gratefully acknowledge the technical help of Neil C. E. Smith. Drs. Harry M. Lander and Thomas Maack provided helpful criticism.
| |
Footnotes |
|---|
Accepted for publication April 15, 1999.
Received for publication February 11, 1999.
1 This work was supported by National Institutes of Health Grants HL-34215, HL-46403, and CA-62948 and in part by a Fellowship of the American Heart Association, New York City Affiliate, to R. M.. A preliminary version of these findings was presented at Experimental Biology '98, April, 1998 (San Francisco, CA) and was published in abstract form in FASEB J 1998;12:A398.
Send reprint requests to: Roberto Levi, M.D., Dept. of Pharmacology, Cornell University Weill Medical College, 1300 York Ave., New York, NY. E-mail: rlevi{at}med.cornell.edu
| |
Abbreviations |
|---|
BK, bradykinin; CGRP, calcitonin gene-related peptide; NE, norepinephrine.
| |
References |
|---|
|
|
|---|
2-adrenoceptors.
Circ Res
78:
475-481This article has been cited by other articles:
![]() |
T. H. Kunz, M. Scott, L. M. Ittner, J. A. Fischer, W. Born, and J. Vogel Calcitonin gene-related peptide-evoked sustained tachycardia in calcitonin receptor-like receptor transgenic mice is mediated by sympathetic activity Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2155 - H2160. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. H. Debarge, B. Sicot, S. Jaillard, I. Gueorgiva, A. Delelis, P. Deruelle, A. S. Ducloy, and L. Storme The Mechanisms of Pain-Induced Pulmonary Vasoconstriction: An Experimental Study in Fetal Lambs Anesth. Analg., April 1, 2007; 104(4): 799 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Katori, D. B. Hoover, J. L. Ardell, R. H. Helm, D. F. Belardi, C. G. Tocchetti, P. R. Forfia, D. A. Kass, and N. Paolocci Calcitonin Gene-Related Peptide In Vivo Positive Inotropy Is Attributable to Regional Sympatho-Stimulation and Is Blunted in Congestive Heart Failure Circ. Res., February 4, 2005; 96(2): 234 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Houfflin-Debarge, A. Delelis, S. Jaillard, B. Larrue, P. Deruelle, A. S. Ducloy, F. Puech, and L. Storme Effects of nociceptive stimuli on the pulmonary circulation in the ovine fetus Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2005; 288(2): R547 - R553. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Strecker, K. Messlinger, M. Weyand, and P. W. Reeh Role of different proton-sensitive channels in releasing calcitonin gene-related peptide from isolated hearts of mutant mice Cardiovasc Res, February 1, 2005; 65(2): 405 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sesti, M. Koyama, M. J. Broekman, A. J. Marcus, and R. Levi Ectonucleotidase in Sympathetic Nerve Endings Modulates ATP and Norepinephrine Exocytosis in Myocardial Ischemia J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 238 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Boehm and H. Kubista Fine Tuning of Sympathetic Transmitter Release via Ionotropic and Metabotropic Presynaptic Receptors Pharmacol. Rev., March 1, 2002; 54(1): 43 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lindenfeld, A. D. Robertson, B. D. Lowes, M. R. Bristow, and for the MOCHA Investigators Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1950 - 1956. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maruyama, E. Hatta, K. Yasuda, N. C. E. Smith, and R. Levi Angiotensin-Converting Enzyme-Independent Angiotensin Formation in a Human Model of Myocardial Ischemia: Modulation of Norepinephrine Release by Angiotensin Type 1 and Angiotensin Type 2 Receptors J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 248 - 254. [Abstract] [Full Text] |
||||
![]() |
R. Levi, R. Maruyama, N. C. E. Smith, and N. Seyedi Is the lower mortality in patients treated with aspirin and angiotensin-converting enzyme inhibitors due to decreased norepinephrine release? J. Am. Coll. Cardiol., March 1, 2000; 35(3): 817 - 818. [Full Text] [PDF] |
||||
![]() |
J. Leor, S. Gottlieb, and S. Behar Reply J. Am. Coll. Cardiol., March 1, 2000; 35(3): 818 - 819. [Full Text] [PDF] |
||||
![]() |
R. Levi and N. C. E. Smith Histamine H3-Receptors: A New Frontier in Myocardial Ischemia J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 825 - 830. [Abstract] [Full Text] |
||||
|
|